Pharmafile Logo
Pharmafocus logo
Advanced Search

Biogen

Showing 15 posts of 117 posts found.

samsung

New data on biosimilars of the big three anti-TNF drugs presented at EULAR 2016

June 8, 2016
Research and Development, Sales and Marketing Benepali, Biogen, Enbrel, Flixabi, Humira, Remicade, Samsung Bioepis, biosimilars, eular 2016, sb5

Samsung Bioepis has presented data at EULAR 2016 on three biosimilars of the highly selling anti-TNF drugs Remicade (infliximab), Enbrel …

News
biogen_austria_238

Biogen MS drug misses primary endpoint in Phase II trial

June 8, 2016
Research and Development Biogen, MS, multiple sclerosis, opicinumab

Biogen has reported top-line results in the Phase II trial evaluating opicinumab (anti-Lingo-1) in relapsing forms of multiple sclerosis, with …

News
biogen_austria_238

Biogen Alzheimer’s treatment accepted into EMA’s PRIME scheme

June 2, 2016
Research and Development, Sales and Marketing Alzheimer's, Biogen, EMA, PRIME, accelerated approval

Biogen (NASDAQ: BIIB) has announced that the European Medicines Agency (EMA) has accepted its investigational treatment for Alzheimer’s disease, aducanumab, …

News
biogen_idec_hillerod_2008

Biogen says European regulatory committee adopts positive view for Tysabri

June 1, 2016
Medical Communications, Research and Development, Sales and Marketing Biogen, CHMP, EMA, Tysabri, multiple sclerosis

Biogen (Nasdaq: BIIB) said the European regulatory committee has backed the approval of a variation to the marketing authorization for its …

News
samsung_bioepis

EU green-lights Samsung Bioepis, Biogen’s Remicade biosimilar Flixabi

May 31, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Biogen, Samsung Bioepis, biosimilar, drug trial, regulation, research

Samsung Bioepis and partner Biogen (Nasdaq: BIIB) said the European Commission has approved Flixabi, a biosimilar version of Johnson & …

News
biogen_idec_hillerod_2008

Biogen signs $2 billion partnership deal with UPenn for gene therapies

May 17, 2016
Research and Development, Sales and Marketing Biogen, collaboration, deal, gene therapy, research

Biogen (Nasdaq: BIIB) said it has signed a deal worth up to $2 billion with the University of Pennsylvania to …

News
biogen_logo

Sobi, Biogen’s haemophilia B therapy gets European approval

May 13, 2016
Medical Communications, Research and Development, Sales and Marketing Biogen, haemophilia B, orphan designation, regulation, sobi

Sobi (STO: SOBI) and Biogen (Nasdaq: BIIB) on Friday said the European Commission has approved their drug to treat haemophilia B. The …

News

Biogen to spin off its haemophilia business

May 4, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Biogen, Business, alprolix, eloctate, haemophilia, hemophilia, spin off, spin-off

Biogen (NASDAQ: BIIB) has announced plans to spin off its haemophilia business as an independent, publicly traded company. To be …

News
biogen_austria_238

EMA recommends Biogen’s MS treatment Zinbryta

May 3, 2016
Research and Development, Sales and Marketing Biogen, CHMP, EMA, daclizumab, zinbryta

The Committee for Medicinal Products for Human Use (CMHP) has recommended the granting of a marketing authorisation for Zinbryta (daclizumab) …

News
biogen_austria_238

New head of R&D at Biogen

April 27, 2016
Research and Development Biogen, Pfizer, R&D, erhlers, michael, michael erhlers, research and development

Biogen (NASDAQ: BIIB) has announced the appointment of Dr Michael Ehlers as executive vice president, research and development. His role …

Appointment
biogen_logo

Biogen Q1 profits rise boosted by Tecfidera sales

April 22, 2016
Medical Communications, Sales and Marketing Biogen, Q1, biotech, earnings, results, tecfidera

Shares in Biogen (Nasdaq: BIIB) climbed to close up over 5% Thursday after the company reported 18% rise in first-quarter …

News
samsung

Samsung Bioepis takes AbbVie to court over attempts to delay Humira biosimilars

April 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, Biogen, Humira, Samsung Bioepis, biosimilars, rheumatoid arthritis

Samsung Bioepis has filed a lawsuit against Abbvie (NYSE: ABBV) to stop the maker of the world’s bestselling drug Humira …

News
Biogen image

Sobi and Biogen’s haemophilia A treatment EU-approved

November 27, 2015
Sales and Marketing Biogen, elocta, haemophilia a, sobi

Elocta, the haemophilia A treatment developed by the Swedish Orphan Biovitrum (Sobi) and Biogen, has received European Commission approval as …

News
mgt_kingsley

Executive vice president Tony Kingsley leaves Biogen

October 22, 2015
Biogen, John Cox, Tony Kingsley

Biogen has begun the search for a replacement for Tony Kingsley, former executive vice president of global commercial operations.Kingsley will …

Appointment
biogen_logo

Revenues up at Biogen – but job losses planned

October 22, 2015
Biogen, financial results, job losses, redundancies

Despite lower than predicted sales of its top-selling products, Biogen has achieved $2.8 billion in revenues in the third quarter …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026